Medindia
Medindia LOGIN REGISTER
Advertisement

Nanoscope Announces Presentations at the Advanced Therapies USA Congress in Philadelphia

Monday, November 11, 2024 Genetics & Stem Cells News
Advertisement
PR Newswire

DALLAS, Nov. 11, 2024

DALLAS, Nov. 11, 2024 /PRNewswire/ -- Nanoscope Therapeutics, Inc., a late-stage clinical biotechnology company developing gene therapies for inherited retinal diseases and age-related macular degeneration (AMD), today announced presentations at the Advanced Therapies USA 2024 congress, being held November 12-13, 2024, in Philadelphia, PA. Details for the presentations are as follows:
Advertisement



Title: Democratizing gene modified cell therapy for neurodegenerative diseasesSession: Track 4: Gene Modified Cell TherapySession Date: Tuesday, November 12, 2024Session Time: 1:30 PM to 1:50 PM EST Location: 120B, Pennsylvania Convention CenterPresenter: Samarendra Mohanty, PhD, President and Chief Scientific Officer
Advertisement

Panel Title: Demonstrating comparability to support regulatory approvalSession Title: Track 7: Viral Vector ManufactureSession Date: Tuesday, November 12, 2024Session Time: 3:30 PM to 4:10 PM ESTLocation: 121B, Pennsylvania Convention CenterPanelist: Khandan Baradaran, PhD, SVP, Regulatory and Quality

Panel Title: Post Market Surveillance and Long-term follow up: How do we make sure the needs for patients are met?Session Title: Track 9: Regulatory Affairs & Policy Session Date: Wednesday, November 13, 2024 Session Time: 11:50 AM to 12:30 PM ESTLocation: 120A, Pennsylvania Convention CenterPanelist: Samarendra Mohanty, PhD, President and Chief Scientific Officer

Panel Title: Safety in gene editingSession Title: Track 5: Gene TherapySession Date: Wednesday, November 13, 2024Session Time: 11:50 AM to 12:30 PM ESTLocation: 120C, Pennsylvania Convention CenterPanelist: Khandan Baradaran, PhD, SVP, Regulatory and Quality

Session Title: Track 9: Regulatory Affairs & PolicySession Date: Wednesday, November 13, 2024Session Time: 3:35 PM ESTLocation: 120A, Pennsylvania Convention CenterChair: Khandan Baradaran, PhD, SVP, Regulatory and Quality

About Nanoscope Therapeutics, Inc.Nanoscope Therapeutics is developing gene-agnostic, sight-restoring optogenetic therapies for the millions of patients blinded by retinal degenerative diseases, for which no cure exists. Following positive end-of-study results from the RESTORE Phase 2b multicenter, randomized, double-masked, sham-controlled clinical trial for RP (NCT04945772), the company announced its plan to initiate a BLA submission for MCO-010 to treat RP in Q1 2025. The company has completed the Phase 2 STARLIGHT trial of MCO-010 therapy in Stargardt patients (NCT05417126) and plans to initiate a Phase 3 registrational trial in Q1 2025. MCO-010 has received FDA Fast Track designations and FDA orphan drug designations for both RP and Stargardt. Preclinical assets include non-viral laser-delivered MCO-020 gene therapy for geographic atrophy.

Investor Contact:Argot [email protected] 

View original content to download multimedia:https://www.prnewswire.com/news-releases/nanoscope-announces-presentations-at-the-advanced-therapies-usa-congress-in-philadelphia-302299901.html

SOURCE Nanoscope Therapeutics
Sponsored Post and Backlink Submission


Latest Press Release on Genetics & Stem Cells News

This site uses cookies to deliver our services.By using our site, you acknowledge that you have read and understand our Cookie Policy, Privacy Policy, and our Terms of Use  Ok, Got it. Close